Projects per year
Fingerprint
- 1 Similar Profiles
Network
Projects
- 1 Active
Research output
-
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
Fan, R., Satilmis, H., Vandewalle, N., Verheye, E., Vlummens, P., Maes, A., Muylaert, C., De Bruyne, E., Menu, E., Evans, H., Chantry, A., De Beule, N., Hose, D., Töngren, M., Eriksson, H., Vanderkerken, K., Maes, K., Breckpot, K. & De Veirman, K., 17 Jan 2023, In: Journal for ImmunoTherapy Of Cancer. 11, 1, e005319.Research output: Contribution to journal › Article › peer-review
-
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism
Satilmis, H., Verheye, E., Vlummens, P., Oudaert, I., Vandewalle, N., Fan, R., Knight, J., De Beule, N., Ates, G., Massie, A., Moreaux, J., Maes, A., De Bruyne, E., Vanderkerken, K., Menu, E., Sloan, E. & De Veirman, K., 17 Oct 2022, In: Journal of pathology. 259, 1, p. 69–80 12 p.Research output: Contribution to journal › Article › peer-review
-
The multifaceted anti-cancer effects of the immunomodulator Tasquinimod in Multiple Myeloma
Fan, R., Verheye, E., Satilmis, H., Vandewalle, N., De Bruyne, E., Menu, E., De Beule, N., Hose, D., Vanderkerken, K., Breckpot, K., Maes, K. & De Veirman, K., 4 Feb 2022.Research output: Unpublished contribution to conference › Poster
-
Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo
Fan, R., Satilmis, H., Vandewalle, N., De Bruyne, E., Menu, E., D Chantry, A., Evans, H., Törngren, M., Eriksson, H., Breckpot, K., Maes, K., Vanderkerken, K. & De Veirman, K., 23 Nov 2021, p. 1594-1594. 1 p.Research output: Unpublished contribution to conference › Poster
-
Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo
Fan, R., Satilmis, H., Vandewalle, N., De Bruyne, E., Menu, E., D Chantry, A., Evans, H., Törngren, M., Eriksson, H., Breckpot, K., Maes, K., Vanderkerken, K. & De Veirman, K., 23 Nov 2021, In: Blood. 138, Supplement 1, p. 651-651 1 p.Research output: Contribution to journal › Meeting abstract (Journal)
-
LSM-PhD day 2022
Niels Vandewalle (Organiser)
29 Mar 2022Activity: Participating in or organising an event › Participation in workshop, seminar
-
AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers
Niels Vandewalle (Contributor) & Kim De Veirman (Speaker)
14 Feb 2020Activity: Talk or presentation › Talk or presentation at a conference
-
AXL: A potential therapeutic target to improve chemosensitivity in Multiple Myeloma (BACR Annual Meeting 2020)
Kim De Veirman (Contributor) & Niels Vandewalle (Speaker)
7 Feb 2020Activity: Talk or presentation › Talk or presentation at a conference
Thesis
-
Targeting AXL, by small molecule inhibitors and Nanobody-based approaches, to eliminate cancer cells and improve chemotherapeutic responses in Acute Myeloid Leukemia
Author: De Veirman, K., Devoogdt, N., Breckpot, K. & Vandewalle, N., 18 Jun 2020Student thesis: Master's Thesis